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Abstract 
X-linked lymphoproliferative disease (XLP) arises from mutations in the SH2D1A gene 
encoding SAP, an intracellular adaptor protein expressed in T, NK and NKT cells. SAP is a 
key regulator of immune function and deficiency causes abnormalities of NK cell 
cytotoxicity, NKT cell development and T cell dependent humoral function. The absence of 
SAP in CD4+ T follicular helper (TFH) cells leads to defective long-term humoral immunity. 
Clinical manifestations are characterised by haemophagocytic lymphohistiocytosis (HLH), 
lymphoma and dysgammaglobulinaemia. Curative treatment is limited to allogeneic 
haematopoietic stem cell transplant with outcome reliant on a good donor match. We have 
previously shown correction of cellular and humoral immune defects in a SAP-/- mouse model 
using lentiviral mediated gene correction in haematopoietic progenitors providing proof of 
concept for gene therapy as a potentially curative treatment. Given that the majority of 
symptoms arise from defective T cell function, we also investigated whether the infusion of 
gene corrected T cells could correct known effector cell defects associated with the condition. 
We initially confirmed that transfer of wild type T lymphocytes into SAP-/- mice improves 
humoral defects characterised in this model. Subsequently CD3+ lymphocytes from SAP-/- 
mice were transduced with a gammaretroviral vector containing codon optimised human SAP 
cDNA before infusion into sub-lethally irradiated SAP-/- recipients. Animals were challenged 
8-10 weeks post- infusion with the T cell dependent antigen NP-CGG and analysis performed 
after 10 days. We demonstrated significant improvement in germinal centre formation and 
NP-specific antibody responses with 20-40% engraftment of gene modified T cells. Using a 
SIN-lentiviral construct with codon optimised SAP transgene expression driven by the 
constitutive EFS promoter, we efficiently transduced XLP patient T cells resulting in 
improved cytotoxicity and TFH cell function in vitro. In addition, using an LCL lymphoma 
model in NSG mice we demonstrated that adoptive transfer of gene corrected patient CTLs 
reduced tumour burden. Overall this data supports the further development of an autologous 
gene corrected T cell approach, which may offer an alternative therapeutic option for patients 
with XLP. 
 
